Grufity logoGrufity logo

Repare Therapeutics Inc. Stock Research

RPTX

9.94USD-0.39(-3.78%)Market Closed

Market Summary

USD9.94-0.39
Market Closed
-3.78%

RPTX Alerts

RPTX Stock Price

RPTX RSI Chart

RPTX Valuation

Market Cap

417.8M

Price/Earnings (Trailing)

-14.38

Price/Sales (Trailing)

3.17

EV/EBITDA

-25.95

Price/Free Cashflow

-1.5K

RPTX Price/Sales (Trailing)

RPTX Profitability

EBT Margin

-10.54%

Return on Equity

-10.39%

Return on Assets

-7.98%

Free Cashflow Yield

-0.07%

RPTX Fundamentals

RPTX Revenue

Revenue (TTM)

131.8M

Revenue Y/Y

164.62%

Revenue Q/Q

-83.83%

RPTX Earnings

Earnings (TTM)

-29.0M

Earnings Y/Y

-11.91%

Earnings Q/Q

-141.95%

Price Action

52 Week Range

8.0718.68
(Low)(High)

Last 7 days

-5.3%

Last 30 days

-15.5%

Last 90 days

-33.4%

Trailing 12 Months

-18.0%

RPTX Financial Health

Current Ratio

4.5

RPTX Investor Care

Shares Dilution (1Y)

0.44%

Diluted EPS (TTM)

-0.69

Peers (Alternatives to Repare Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.4T
387.5B
-0.56% -0.91%
25.47
6.25
2.44% -5.35%
2.0T
204.1B
-1.92% -6.89%
29.31
9.69
10.38% -5.25%
1.2T
282.8B
1.63% -25.54%
20.69
4.39
9.78% -21.12%
985.3B
514.0B
-3.36% -34.72%
-361.97
1.92
9.40% -108.16%
MID-CAP
3.3B
258.4M
203.99% 176.76%
-11.18
12.92
24.91% -254.56%
2.3B
9.2B
-18.97% -49.38%
-6.25
0.25
51.67% -98.90%
SMALL-CAP
1.6B
1.7B
-22.36% -14.62%
13.28
0.94
61.79% 371.82%
1.4B
602.5M
-17.77% -52.80%
-2.5
2.4
18.18% -18.59%
1.1B
418.9M
5.51% -56.16%
-2.97
2.6
-9.85% -101.06%
986.8M
478.9M
-11.35% -65.42%
-0.31
2.06
-31.50% -634.70%
954.9M
482.4M
-16.25% -37.64%
-4.12
1.98
33.15% -170.42%
841.2M
50.8M
-34.66% -77.56%
-1.07
16.55
1229.98% -13.59%
791.6M
1.1B
-10.56% -33.33%
27.44
0.72
-5.82% -92.23%
286.8M
10.3M
-24.84% -63.38%
-1.02
27.94
478.23% 7.85%

Financials for Repare Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue45.7%131,830,00090,500,66749,171,3337,842,0007,600,000
Operating Expenses1.5%151,626,000149,407,000142,218,000129,751,000116,260,000
  S&GA Expenses0.9%32,560,00032,260,00030,952,00029,755,00026,213,000
  R&D Expenses1.6%119,066,000117,147,000111,266,00099,996,00090,047,000
EBITDA92.4%-9,956,000-131,311,000-119,852,000-106,875,000-
EBITDA Margin99.5%-0.08-15.93-15.28--
Earnings Before Taxes46.5%-13,900,000-25,972,000-133,087,000-121,757,000-108,586,000
EBT Margin63.3%-0.11-0.29-16.15-15.53-
Interest Expenses719.2%1,966,000240,000---
Net Income-13.1%-29,047,000-25,679,000-132,032,000-120,248,000-106,908,000
Net Income Margin22.3%-0.22-0.28-16.02-15.33-
Free Cahsflow-104.2%-280,0006,734,000-114,255,000-102,980,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-11.0%364409308337369
  Current Assets-9.4%354391290319351
    Cash Equivalents2.8%160155276305334
  Net PPE-9.7%4.005.005.005.006.00
Liabilities-18.2%85.0010383.0078.0080.00
  Current Liabilities27.1%79.0062.0039.0034.0035.00
Shareholder's Equity-8.6%280306226259288
  Retained Earnings-15.2%-239-207-283-245-210
  Additional Paid-In Capital15.7%37.0032.0027.0023.0018.00
Accumulated Depreciation-3.00----
Shares Outstanding0.2%42.0042.0042.0042.0042.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-96.5%3229,221-111,710-101,575-85,796
  Share Based Compensation6.7%19,69118,44917,08915,52712,829
Cashflow From Investing16.4%-175,778-210,234-1,693-501-1,676
Cashflow From Financing-99.1%88095,27795,37195,61595,557

Risks for RPTX

What is the probability of a big loss on RPTX?

97.9%


Probability that Repare Therapeutics stock will be more than 20% underwater in next one year

96.5%


Probability that Repare Therapeutics stock will be more than 30% underwater in next one year.

52.8%


Probability that Repare Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RPTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repare Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for RPTX

Cumulative Returns on RPTX

Which funds bought or sold RPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-06
Rockefeller Capital Management L.P.
new
-
2,000
2,000
-%
2023-02-15
JANE STREET GROUP, LLC
new
-
414,778
414,778
-%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
new
-
114,000
114,000
-%
2023-02-14
STATE OF WISCONSIN INVESTMENT BOARD
reduced
-6.56
28,126
239,126
-%
2023-02-14
DIFESA CAPITAL MANAGEMENT, LP
unchanged
-
39,769
226,769
0.18%
2023-02-14
Deep Track Capital, LP
reduced
-12.79
2,184,080
40,123,100
1.69%
2023-02-14
Jump Financial, LLC
added
53.85
190,880
411,880
0.02%
2023-02-14
XTX Topco Ltd
new
-
367,294
367,294
0.08%
2023-02-14
Qube Research & Technologies Ltd
reduced
-12.83
8,867
156,867
-%
2023-02-14
BIOIMPACT CAPITAL LLC
reduced
-
4,231,180
24,122,200
6.26%

1–10 of 47

Latest Funds Activity

Are funds buying RPTX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RPTX
No. of Funds

Repare Therapeutics News

Business Wire

Repare Therapeutics Announces Plenary Oral Presentation at the ....

Business Wire,
37 hours ago

Investing.com India

Armenian Reporter

ETF Daily News

Investors Chronicle

Bargain Shares 2023 - Investors' Chronicle.

Investors Chronicle,
35 days ago

Schedule 13G FIlings of Repare Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
deep track capital, lp
6.50%
2,727,606
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
10.6%
4,443,423
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
0.1%
26,894
SC 13G/A
Feb 14, 2023
redmile group, llc
6.4%
2,684,396
SC 13G/A
Feb 13, 2023
chi advisors llc
6.67%
2,800,126
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 06, 2023
versant venture capital v, l.p.
1.3%
563,403
SC 13D/A
Jun 13, 2022
versant venture capital v, l.p.
2.0%
850,560
SC 13D/A
Jun 06, 2022
biotechnology value fund l p
10.4%
4,368,757
SC 13G/A
Feb 14, 2022
redmile group, llc
6.7%
2,789,496
SC 13G/A

RPTX Fair Value

Recent SEC filings of Repare Therapeutics

View All Filings
Date Filed Form Type Document
Mar 10, 2023
8-K
Current Report
Mar 01, 2023
S-8
Employee Benefits Plan
Feb 28, 2023
10-K
Annual Report
Feb 28, 2023
8-K
Current Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 13, 2023
SC 13G/A
Major Ownership Report
Feb 10, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for RPTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-30
Segal Lloyd Mitchell
acquired
-
-
78,550
president and ceo
2023-01-30
Koehler Maria
acquired
-
-
26,450
evp, chief medical officer
2023-01-30
Zinda Michael
acquired
-
-
24,550
evp, chief scientific officer
2023-01-30
Forte Steve
acquired
-
-
24,530
evp, chief financial officer
2022-12-29
Jerel Davis
acquired
-
-
4,254
-
2022-12-29
Jerel Davis
acquired
-
-
70,678
-
2022-12-20
Koehler Maria
acquired
100,040
2.06238
48,507
evp, chief medical officer
2022-12-09
Jerel Davis
sold
-4,000,000
16.00
-250,000
-
2022-06-13
BVF PARTNERS L P/IL
bought
1,898,820
12.73
149,161
-
2022-06-06
Jerel Davis
acquired
-
-
151,202
-

1–10 of 50

Lloyd M. Segal
150
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

RPTX Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue:  
Collaboration agreements$ 131,830$ 7,600
Operating expenses:  
Research and development, net of tax credits119,06690,047
General and administrative32,56026,213
Total operating expenses151,626116,260
Loss from operations(19,796)(108,660)
Other income (expense), net  
Realized and unrealized gain (loss) on foreign exchange308(144)
Interest income5,631259
Other expense, net(43)(41)
Total other income, net5,89674
Loss before income taxes(13,900)(108,586)
Income tax (expense) benefit(15,147)1,678
Net loss(29,047)(106,908)
Unrealized loss on available-for-sale marketable securities(428)0
Total other comprehensive loss(428)0
Comprehensive loss$ (29,475)$ (106,908)
Net loss per share attributable to common shareholders--basic$ (0.69)$ (2.83)
Net loss per share attributable to common shareholders--diluted$ (0.69)$ (2.83)
Weighted-average common shares outstanding-basic41,922,04237,818,115
Weighted-average common shares outstanding-diluted41,922,04237,818,115

RPTX Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 159,521$ 334,427
Marketable securities184,4207,439
Research and development tax credits receivable1,2802,580
Collaboration revenue receivable1,5250
Other receivables1,518654
Prepaid expenses5,7156,314
Total current assets353,979351,414
Property and equipment, net4,2285,604
Operating lease right-of-use assets5,3717,491
Other assets497586
Deferred tax assets03,620
TOTAL ASSETS364,075368,715
Current liabilities:  
Accounts payable4612,302
Accrued expenses and other current liabilities21,64518,622
Operating lease liabilities, current portion2,1711,721
Deferred revenue, current portion53,10211,921
Income tax payable1,240523
Total current liabilities78,61935,089
Operating lease liabilities, net of current portion3,2575,592
Deferred revenue, net of current portion2,68239,613
TOTAL LIABILITIES84,55880,294
Commitments and Contingencies
SHAREHOLDERS' EQUITY:  
Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of December 31, 2022, and December 31, 2021, respectively00
Common shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021; 42,036,193 and 41,850,162 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively482,032480,699
Additional paid-in capital37,22617,988
Accumulated other comprehensive loss(428)0
Accumulated deficit(239,313)(210,266)
TOTAL SHAREHOLDERS' EQUITY279,517288,421
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 364,075$ 368,715